NABRIVA THERAPEUTICS
Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections. Nabriva Therapeutics received U.S. Food and Drug Administration approval for XENLETA® (lefamulin injection, lefamulin tablets), the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia (CABP). Nabriva Therapeutics is also developing CONTEPO™ (fosfomycin) for injection, a potential first-in-class epox... ide antibiotic for complicated urinary tract infections (cUTI), including acute pyelonephritis. Nabriva entered into an exclusive agreement with subsidiaries of Merck & Co. Inc., Kenilworth, N.J., USA to market, sell and distribute SIVEXTRO® (tedizolid phosphate) in the United States and certain of its territories.
NABRIVA THERAPEUTICS
Social Links:
Industry:
Biotechnology Health Care Medical
Founded:
2001-01-01
Address:
Vienna, Wien, Austria
Country:
Austria
Website Url:
http://www.nabriva.com
Total Employee:
101+
Status:
Active
Contact:
(430) 174-0930
Email Addresses:
[email protected]
Total Funding:
325.87 M USD
Technology used in webpage:
LetsEncrypt IPv6 New Relic Mobile Optimized FLoC Opt-Out FLoC Drupal Akamai Hosted Adobe Dynamic Tag Management LiveChat
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
PIQUR Therapeutics
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
Salix Pharmaceuticals
Salix Pharmaceuticals is a specialty pharmaceutical company focused on the prevention and treatment of gastrointestinal disorders.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
Date | Company | Article | Price |
---|---|---|---|
2018-07-25 | Zavante Therapeutics | Zavante Therapeutics acquired by Nabriva Therapeutics | N/A |
Investors List
Armentum Partners
Armentum Partners investment in Post-IPO Debt - Nabriva Therapeutics
Hercules Capital
Hercules Capital investment in Post-IPO Debt - Nabriva Therapeutics
Novartis Venture Fund
Novartis Venture Fund investment in Series B - Nabriva Therapeutics
GLS Ventures
GLS Ventures investment in Series B - Nabriva Therapeutics
EcoR1 Capital
EcoR1 Capital investment in Series B - Nabriva Therapeutics
Wellcome Trust
Wellcome Trust investment in Series B - Nabriva Therapeutics
HBM Healthcare Investments AG
HBM Healthcare Investments AG investment in Series B - Nabriva Therapeutics
OrbiMed
OrbiMed investment in Series B - Nabriva Therapeutics
Phase4 Partners
Phase4 Partners investment in Series B - Nabriva Therapeutics
Vivo Capital
Vivo Capital investment in Series B - Nabriva Therapeutics
Key Employee Changes
Date | New article |
---|---|
2021-10-01 | Nabriva Therapeutics Appoints Dr. Christine Guico-Pabia, M.D., as Chief Medical Officer |
Official Site Inspections
http://www.nabriva.com Semrush global rank: 8.11 M Semrush visits lastest month: 365
- Host name: 52.176.165.69
- IP address: 52.176.165.69
- Location: Des Moines United States
- Latitude: 41.6006
- Longitude: -93.6112
- Metro Code: 679
- Timezone: America/Chicago
- Postal: 50307